Tandem Nano Ltd (TNL) is a University of Liverpool (UoL) start-up focused on the development of its proprietary SDN (Solid Drug Nanoparticle) technology platform which has the potential to transform the delivery of active compounds in industries as diverse as pharmaceuticals to agrochemicals.
Antony has an extensive background in the development and commercialisation of both early and late stage medical technology. Over a period of 30 plus years he has worked for major companies such as Johnson & Johnson and Fresenius in a range of senior positions. Latterly he has worked with early stage spin out companies as CEO and has successfully built businesses in a number of fields. In his last position as CEO of Tissue Regenix Group plc he built the company over a period of 9 years to be a listed multi-national organisation raising over £80m to fund its development plan and its first acquisition.
Antony is a Board Director of NorthInvest a major Angel network based in Leeds as well a Director in a number of early stage lifescience companies.
Andrew Owen PhD FRSB FBPhS FLSW
Professor of Pharmacology, University of Liverpool
Andrew Owen is Professor of Pharmacology at the University of Liverpool, UK. He is Chair of the British Society for Nanomedicine, a fellow of the Royal Society of Biology, a fellow of the British Pharmacological Society, and a fellow of the Learned Society of Wales. His clinical and basic research focuses on understanding mechanisms that underpin inter-patient variability in pharmacokinetics and pharmacodynamics. A major emphasis has been to employ knowledge of these mechanisms to accelerate the translation of technologies to clinical applications for oral and long-acting drug delivery. His ongoing research portfolio is funded by NIH, USAID, EPSRC, EC and pharmaceutical and charitable agencies. He has published over 200 peer-reviewed papers, is co-inventor of patents relating to drug delivery. Professor Owen also co-leads the UK contribution to the H2020-funded European Nanomedicine Characterisation Laboratory (www.EUNCL.eu) and a modelling core for the NIH-funded Long-acting/Extended release Antiretroviral resource Program (www.LEAPresources.org).
Lee Tatham BSc(Hons) PhD
Lee completed his BSc in microbiology at The University of Liverpool (UK) in 2007. Following this, he undertook a PhD concerning the antimicrobial efficacy and mode of action of solid drug nanoparticles, graduating in 2011. Lee remained at The University of Liverpool completing postdoctoral positions focusing on the pharmacological assessment of novel nanoscale drug delivery systems and their application to HIV-therapy. Lee has expertise in the development and application of pre-clinical models to assess the pharmacokinetics and bio-distribution of drug-loaded nanoparticles. Additionally, Lee has experience of assessing the mechanisms that underpin the transport of nanoparticles across biological barriers. He has published a number of original and review articles concerning the application of nanotechnology to drug delivery, is co-inventor of patents relating to the application of nanotechnology to drug delivery and is a founding member of the British Society for Nanomedicine.
Steve Rannard BSc(Hons) DPhil FRSC
Professor of Chemistry, University of Liverpool
Steve Rannard is a materials chemist and, after 16 years in industry (Cookson, Courtaulds, Unilever), joined the University of Liverpool (UK) as a Professor of Chemistry in 2007. His medical research focuses materials science onto unmet clinical needs (oral, long-acting and topical administration) through scalable nanoparticle platforms. In addition, considerable non-clinical wok targets the improvement usage and efficacy of poorly water-soluble compounds in a range of market sectors. He has co-founded three start-up companies and is the vice-Chair of the British Society for Nanomedicine. Scientific recognition includes the RSC/Macro Group UK Young Researcher of the Year Medal (first recipient), sequential RSC Industrial Lectureships (Strathclyde, ’01; Sussex, ‘02), visiting Lectureship at Sussex (‘99-‘01), visiting Professorship at UoL (‘03-‘07) and a Royal Society Industry Fellowship (’05-‘09). He has co-authored >150 scientific publications and is co-inventor of >90 patent families. His research funding includes grants from MRC, EPSRC, NIH, USAID, CRUK, CHAI, BSAC and global industry.